Monogenic obesity in humans

Annual Review of Medicine

Volumn 56, Issue , 2005, Pages 443-458

  Farooqi, I Sadaf ^a   O'Rahilly, Stephen ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Genetics; Leptin; Syndromes

Indexed keywords

LEPTIN; LEPTIN RECEPTOR; MELANOCORTIN 4 RECEPTOR; PROOPIOMELANOCORTIN; RECOMBINANT LEPTIN;

ALBRIGHT SYNDROME; ALSTROM SYNDROME; BARDET BIEDL SYNDROME; BORJESON FORSSMAN LEHMANN SYNDROME; CLINICAL FEATURE; COHEN SYNDROME; CONGENITAL LEPTIN DEFICIENCY; DEVELOPMENTAL DISORDER; ENERGY BALANCE; FRAGILE X SYNDROME; GENE DISRUPTION; GENETIC ASSOCIATION; GENETIC COUNSELING; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; INHERITANCE; LEPTIN RECEPTOR DEFICIENCY; MAMMAL; MELANOCORTIN 4 DEFICIENCY; MISSENSE MUTATION; MOLECULAR CLONING; MONOGENIC DISORDER; MONOGENIC OBESITY; NONHUMAN; OBESITY; PLEIOTROPY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROHORMONE CONVERTASE 1 DEFICIENCY; PROOPIOMELANOCORTIN DEFICIENCY; REVIEW; SIGNAL TRANSDUCTION; ULNAR MAMMARY SYNDROME; WAGR SYNDROME;

ADOLESCENT; ANIMALS; CHILD; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; DNA MUTATIONAL ANALYSIS; ENERGY METABOLISM; GENETIC COUNSELING; GENETIC DISEASES, INBORN; HOMEOSTASIS; HUMANS; LEPTIN; MICE; MICE, OBESE; OBESITY; OBESITY, MORBID; PHENOTYPE; PROGNOSIS; RECEPTOR, MELANOCORTIN, TYPE 4; SIGNAL TRANSDUCTION; SYNDROME;

EID: 14544272858     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.56.062904.144924     Document Type: Review

References (62)

1. Kopelman PG. 2000. Obesity as a medical problem. Nature 404:635-43
2. Seidell JC. 2000. Obesity, insulin resistance and diabetes - a worldwide epidemic. Br. J. Nutr. 83(Suppl. 1):S5-8
3. Maes HH, Neale MC, Eaves LJ. 1997. Genetic and environmental factors in relative body weight and human adiposity. Behav. Genet. 27:325-51
4. Comuzzie AG. 2002. The emerging pattern of the genetic contribution to human obesity. Best Pract. Res. Clin. Endocrinol. Metab. 16:611-21
5. Cummings DE, Schwartz MW. 2003. Genetics and pathophysiology of human obesity. Annu. Rev. Med. 54:453-71
6. Friedman JM, Halaas JL. 1998. Leptin and the regulation of body weight in mammals. Nature 395:763-70
7. Schwartz MW, Woods SC, Porte D, et al. 2000. Central nervous system control of food intake. Nature 404:661-71
8. Coll AP, Farooqi IS, Challis BG, et al. 2004. Proopiomelanocortin and energy balance: insights from human and murine genetics. J. Clin. Endocrinol. Metab. 89: 2557-62
9. Zigman JM, Elmquist JK. 2003. Minireview: from anorexia to obesity - the yin and yang of body weight control. Endocrinology 144:3749-56
10. Ahima RS, Prabakaran D, Mantzoros C, et al. 1996. Role of leptin in the neuroendocrine response to fasting. Nature 382:250-52
11. Flier JS. 1998. Clinical review 94: What's in a name? In search of leptin's physiologic role. J. Clin. Endocrinol. Metab. 83:1407-13
12. Montague CT, Farooqi IS, Whitehead JP, et al. 1997. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387:903-8
13. Farooqi IS, Matarese G, Lord GM, et al. 2002 Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110:1093-103
14. Strobel A, Issad T, Camoin L, et al. 1998. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat. Genet. 18:213-15
15. Ozata M, Ozdemir IC, Licinio J. 1999. Human leptin deficiency caused by a missense mutation: Multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J. Clin. Endocrinol. Metab. 84:3686-95
16. Licinio J, Caglayan S, Ozata M, et al. 2004. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc. Natl. Acad. Sci. USA 101:4531-36
17. Farooqi IS, Jebb SA, Langmack G, et al. 1999. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341:879-84
18. Flier JS, Harris M, Hollenberg AN. 2000. Leptin, nutrition, and the thyroid: the why, the wherefore, and the wiring. J. Clin. Invest. 105:859-61
19. Lord GM, Matarese G, Howard JK, et al. 1998. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394:897-901
20. Clement K, Vaisse C, Lahlou N, et al. 1998. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392:398-401
21. Krude H, Gruters A. 2000. Implications of proopiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome. Trends Endocrinol. Metab. 11:15-22
22. Krude H, Biebermann H, Schnabel D, et al. 2003. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J. Clin. Endocrinol. Metab. 88:4633-40
23. Krude H, Biebermann H, Luck W, et al. 1998 Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat. Genet. 19:155-57
24. Challis BG, Pritchard LE, Creemers JW, et al. 2002. A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. Hum. Mol. Genet. 11:1997-2004
25. Yeo GS, Farooqi IS, Aminian S, et al. 1998. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat. Genet. 20:111-12
26. Vaisse C, Clement K, Guy-Grand B, et al. 1998. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat. Genet. 20:113-14
27. Farooqi IS, Keogh JM, Yeo GS, et al. 2003. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N. Engl. J. Med. 348:1085-95
28. Jackson RS, Creemers JW, Ohagi S, et al. 1997. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat. Genet. 16:303-6
29. Jackson RS, Creemers JW, Farooqi IS, et al. 2003. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J. Clin. Invest. 112:1550-60
30. O'Rahilly S, Farooqi IS, Yeo GS, et al. 2003. Minireview: human obesity-lessons from monogenic disorders. Endocrinology 144:3757-64
31. Katsanis N AS, Badano JL, Eichers ER, et al. 2001. Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science 293:2256-59
32. Katsanis N. 2004. The oligogenic properties of Bardet-Biedl syndrome. Hum. Mol. Genet. 13(Spec. No. 1):R65-71
33. Mykytyn K, Nishimura DY, Searby CC, et al. 2002. Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome. Nat. Genet. 31: 435-38
34. Katsanis N, Beales PL, Woods MO, et al. 2000. Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome. Nat. Genet. 26:67-70
35. Badano JL, Ansley SJ, Leitch CC, et al. 2003. Identification of a novel Bardet-Biedl syndrome protein, BBS7, that shares structural features with BBS1 and BBS2. Am. J. Hum. Genet. 72:650-58
36. Ansley SJ, Badano JL, Blacque OE, et al. 2003. Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. Nature 425:628-33
37. Li JB, Gerdes JM, Haycraft CJ, et al. 2004. Comparative genomics identifies a flagellar and basal body proteome that includes the BBS5 human disease gene. Cell 117:541-52
38. Mykytyn K, Braun T, Carmi R, et al. 2001. Identification of the gene that, when mutated, causes the human obesity syndrome BBS4. Nat. Genet. 28:188-91
39. Kim JC, Badano JL, Sibold S, et al. 2004. The Bardet-Biedl protein BBS4 targets cargo to the pericentriolar region and is required for microtubule anchoring and cell cycle progression. Nat. Genet. 36:462-70
40. Mykytyn K, Mullins RF, Andrews M, et al. 2004. Bardet-Biedl syndrome type 4 (BBS4)-null mice implicate Bbs4 in flagella formation but not global cilia assembly. Proc. Natl. Acad. Sci. USA 101:8664-69
41. Weinstein LS, Chen M, Liu J. 2002. Gs(alpha) mutations and imprinting defects in human disease. Ann. NY Acad. Sci. 968:173-97
42. Weinstein LS, Yu S, Liu J. 2002. Analysis of genomic imprinting of Gs alpha gene. Methods Enzymol. 344:369-83
43. Jin P, Warren ST. 2003. New insights into fragile X syndrome: from molecules to neurobehaviors. Trends Biochem. Sci. 28:152-58
44. Hagerman PJ, Hagerman RJ. 2004. The fragile-X premutation: a maturing perspective. Am. J. Hum. Genet. 74:805-16
45. Lower KM, Turner G, Kerr BA, et al. 2002. Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome. Nat. Genet. 32:661-65
46. Cohen MM Jr, Hall BD, Smith DW, et al. 1973. A new syndrome with hypotonia, obesity, mental deficiency, and facial, oral, ocular, and limb anomalies. J. Pediatr. 83:280-84
47. Chandler KE, Kidd A, Al-Gazah L, et al. 2003. Diagnostic criteria, clinical characteristics, and natural history of Cohen syndrome. J. Med. Genet. 40:233-41
48. Russell-Eggitt IM, Clayton PT, Coffey R, et al. 1998. Alström syndrome. Report of 22 cases and literature review. Ophthalmology 105:1274-80
49. Michaud JL, Heon E, Guilbert F, et al. 1996. Natural history of Alström syndrome in early childhood: onset with dilated cardiomyopathy. J. Pediatr. 128: 225-29
50. Collin GB, Marshall JD, Ikeda A, et al. 2002. Mutations in ALMS 1 cause obesity, type 2 diabetes and neurosensory degeneration in Alstróm syndrome. Nat. Genet. 31:74-78
51. Bamshad M, Lin RC, Law DJ, et al. 1997. Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Nat. Genet. 16:311-15
52. Carlson H, Ota S, Campbell CE, et al. 2001. A dominant repression domain in Tbx3 mediates transcriptional repression and cell immortalization: relevance to mutations in Tbx3 that cause ulnar-mammary syndrome. Hum. Mol. Genet. 10:2403-13
53. Davenport TG, Jerome-Majewska LA, Papaioannou VE. 2003. Mammary gland, limb and yolk sac defects in mice lacking Tbx3, the gene mutated in human ulnar mammary syndrome. Development 130: 2263-73
54. Goldstone AP. 2004. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol. Metab. 15:12-20
55. Butler M. 1990. Prader-Willi syndrome: current understanding of cause and diagnosis. Am. J. Med. Genet. 35:319-32
56. Haqq AM, Farooqi IS, O'Rahilly S, et al. 2003. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 88:174-78
57. Cummings DE, Clement K, Purnell JQ, et al. 2002. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat. Med. 8:643-44
58. Holder JL Jr, Butte NF, Zinn AR. 2000. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum. Mol. Genet. 9:101-8
59. Michaud JL, Boucher F, Melnyk A, et al. 2001. Sim1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum. Mol. Genet. 10:1465-73
60. Faivre L, Cormier-Daire V, Lapierre JM, et al. 2002. Deletion of the SIM1 gene (6q16.2) in a patient with a Prader-Willi-like phenotype. J. Med. Genet. 39:594-96
61. Rose EA, Glaser T, Jones C, et al. 1990. Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms' tumor gene. Cell 60:495-508
62. Gul D, Ogur G, Tunca Y, et al. 2002. Third case of WAGR syndrome with severe obesity and constitutional deletion of chromosome (11)(p12p14). Am. J. Med. Genet. 107:70-71